CALHM1 (Calcium Homeostasis Modulator 1) is a transmembrane protein involved in regulating extracellular calcium sensing, ATP release, and neuronal excitability. It forms voltage-gated ion channels that mediate the flux of ions and metabolites, playing roles in taste perception, brain function, and metabolic regulation. CALHM1 has garnered attention for its association with Alzheimer’s disease, as genetic variants may influence amyloid-beta pathology. Antibodies targeting CALHM1 are essential tools for studying its expression, localization, and function. These antibodies are typically developed against specific epitopes, such as extracellular or intracellular domains, and validated for applications like Western blotting, immunohistochemistry, and flow cytometry. They enable researchers to investigate CALHM1's involvement in physiological processes, including synaptic plasticity, calcium signaling, and neurodegeneration. Recent studies also explore CALHM1's potential as a therapeutic target, driving demand for high-specificity antibodies. Challenges include ensuring minimal cross-reactivity with homologous proteins (e.g., CALHM2/3) and optimizing detection in diverse tissue types. Commercial and custom CALHM1 antibodies facilitate mechanistic insights into its role in diseases, aiding drug discovery and biomarker development. Ongoing research aims to clarify its structure-function relationships and pathophysiological contributions.